Report #NBU-7FBF3AA8Framework v5.9Pipeline v0.4Evaluated 08 Oct 2026OECD: 3.1 Basic medicineBasis: Full textType: Laboratory experiment

Short RNA chaperones promote aggregation-resistant TDP-43 conformers to mitigate neurodegeneration.

Item: Short RNA chaperones promote aggregation-resistant TDP-43 conformers to mitigate neurodegeneration.
Rating: 4.1
Author: Nabu

Copley et al.Copley, Mauna, Danielson et al.2026Science (New York, N.Y.)10.1126/science.adv3301

Primary claim

These short RNAs engage and stabilize the TDP-43 RNA recognition motifs, which allosterically destabilizes a conserved helical region in the prion-like domain, thereby promoting aggregation-resistant conformers.

Supported · Converging hydrogen-exchange, NMR, binding and simulation evidence; causal sufficiency of helix destabilisation inferred rather than directly tested.

In brief

Defines how short RNAs allosterically remodel TDP-43 into aggregation-resistant conformers and reverses pathology in mice, constrained by a single acute preclinical model.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓

Abstract

Aberrant aggregation of the prion-like RNA binding protein TDP-43 drives several fatal neurodegenerative proteinopathies, including amyotrophic lateral sclerosis (ALS). In this work, we define how short, specific RNAs solubilize TDP-43. These short RNAs engage and stabilize the TDP-43 RNA recognition motifs, which allosterically destabilizes a conserved helical region in the prion-like domain, thereby promoting aggregation-resistant conformers. Sequence-space mining identified short RNA chaperones with enhanced activity against TDP-43 and disease-linked variants. Enhanced short RNA chaperones mitigated aberrant TDP-43 phenotypes in optogenetic models and in ALS patient-derived and control motor neurons. In mice with cytoplasmic TDP-43 aggregation and motor neuron loss, an enhanced short RNA chaperone reduced pathological aggregation, restored TDP-43 function, and conferred neuroprotection. These results define a mechanistic and therapeutic framework for RNA-based strategies to counter TDP-43 proteinopathies.

Key Claims

Primary findingSupported

Converging hydrogen-exchange, NMR, binding and simulation evidence; causal sufficiency of helix destabilisation inferred rather than directly tested.

Abstract; Results, Figs. 1–2

Quote verified

SecondaryTentative

In mice with cytoplasmic TDP-43 aggregation and motor neuron loss, an enhanced short RNA chaperone reduced pathological aggregation, restored TDP-43 function, and conferred neuroprotection.

One acute overexpression model, 3–5 day follow-up, saline-only comparator, function read at a single splicing target, no behavioural endpoints.

Abstract; Results, Fig. 6

Quote verified

SecondarySupported

Enhanced short RNA chaperones mitigated aberrant TDP-43 phenotypes in optogenetic models and in ALS patient-derived and control motor neurons.

Consistent rescue across two systems, but few patient lines, one control line, and some imaging sample sizes not stated.

Abstract; Results, Fig. 5 and figs. S21–S25

Quote verified

SecondarySupported

Malat1_start emerged as the most potent natural RNA chaperone, with the lowest IC50 values against WT TDP-43 (IC50~0.36 μM) and disease-linked variants (IC50~0.17 μM–0.44 μM).

Dose-response IC50 panels across many variants on one assay platform; potency margin over the prior lead is modest.

Results, Mining section; Fig. 4B

Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Mechanism supported by four orthogonal methods

The allosteric link from RNA recognition motif engagement to destabilisation of the prion-like domain's conserved region is built from domain-deletion biochemistry, hydrogen/deuterium-exchange mass spectrometry with at least 87.9% sequence coverage across a 1 s to 14.5 h timescale, NMR chemical shift perturbations, and all-atom molecular dynamics. Bimodal mass spectra at early timepoints further show that RNA binding depopulates the more stabilised conserved-region conformer.

↳ Results, Figs. 1–2 and figs. S5–S14

#contribution

Functional counter-screen disqualifies a potent candidate

Rather than advancing the tightest binder, the work uses a TDP-43 loss-of-function biosensor to show that (UG)17 blocks aggregation while impairing TDP-43 function, and removes it from development. This is a substantive use of a negative result to constrain the therapeutic hypothesis and cautions against affinity-only screening.

↳ Results, CUTS biosensor section, fig. S21G; Discussion

#methodological rigour

Randomised, blinded, powered in vivo experiment

The mouse study reports a prospective power calculation, randomisation of TDP-43ΔNLS animals to saline or RNA, motor-neuron counting by a blinded second individual, stated inclusion criteria based on YFP confirmation, and no attrition. Target engagement is independently evidenced by partial colocalisation of Cy5-labelled RNA with TDP-43 puncta.

↳ Materials and Methods, Animals and Animal Data Analysis Considerations; Fig. 6; fig. S26

#contribution

Breadth across disease-relevant TDP-43 forms

Chaperone activity is quantified by IC50 against eight missense variants and five post-translational modification mimetics, including the K145/K192Q acetylation mimetic that defeats the prior lead. Identifying an RNA that retains activity against that variant addresses a concrete translational concern about patient heterogeneity.

↳ Results, Figs. 3–4 and figs. S15–S17

Limitations

#methodological rigour

No matched control oligonucleotide in vivo

The mouse experiment compares RNA treatment against saline only. Without a sequence-matched, non-binding oligonucleotide of the same 2'OMe and phosphorothioate chemistry, non-specific effects of the modified backbone on the observed neuroprotection and aggregate reduction are not excluded.

↳ Materials and Methods, Spinal Delivery of RNA; Fig. 6

#contribution

Single acute, single-sex in vivo model

In vivo efficacy rests on one acute AAV9 TDP-43ΔNLS overexpression paradigm in female C57BL/6J mice, with a single dose delivered by laminectomy and gelfoam application and outcomes read 3–5 days later. No behavioural, motor or survival endpoints are reported, and function is assessed at a single splicing target.

↳ Materials and Methods, Animals and Intraspinal Delivery; Fig. 6

#methodological rigour

Hydrogen-exchange differences binned without statistics

Consensus exchange difference maps are produced by manually scoring peptides into ±10%, ±20% and ±30% bins and rounding the per-residue average, with no statistical test and with the stated caveat that the displayed values do not report the actual percentage difference or proximity to each cutoff.

↳ Materials and Methods, HXMS Data Visualization

#positioning

Translational limits absent from limitations section

The discussion names additional mouse models, broader patient-line diversity and further RNA optimisation as limitations, but does not address the invasive surgical delivery route, the female-only cohort, or the short follow-up when asserting translational implications for symptomatic patients.

↳ Discussion, limitations paragraph and preceding in vivo paragraph

#methodological rigour

Semi-quantitative and technical-replicate cellular readouts

Cryptic splicing of STMN2 and KCNQ2 is quantified from band intensity after 40 PCR cycles, which saturates, and is shown only in control neurons under arsenite stress. Neuritic granule measurements are averaged over 20–25 neurites in four technical replicates of the same lines rather than independent biological replicates.

↳ Materials and Methods, RT-PCR and iPSC-derived neuron treatment and immunostaining; figs. S23–S25

Does this match your read? Add your assessment ↓

Nabu Commentary

Assessment converged on the mechanistic core and diverged on how much weight the in vivo chapter can bear. The hydrogen/deuterium-exchange, NMR, domain-deletion and simulation evidence in Figs. 1–2 form an unusually well-cross-checked account of how RNA binding at the recognition motifs propagates to destabilise the conserved helix, and the IC50 panels in Figs. 3–4 extend it credibly across missense variants and modification mimetics. The mouse experiment in Fig. 6 is randomised, powered and blinded for motor-neuron counting, yet it compares against saline rather than a chemistry-matched non-binding oligonucleotide, reads out 3–5 days after a single surgically delivered dose in female mice, and assesses function at one splicing target — which is why the in vivo claim is treated more cautiously than the mechanism. Methodological detail elsewhere is uneven: hydrogen-exchange differences are binned manually without a statistical test, and cryptic-splicing rescue is quantified from saturating 40-cycle endpoint PCR. The Discussion's statement of direct translational implications for symptomatic patients reaches beyond what a 5-day acute model shows, and the limitations section does not name the invasive delivery route or single-sex design.

Check another paper

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Study Quality

Strong4.1

Confidence medium

Contribution

4.3

The paper resolves five explicitly named unknowns, moving from domain mapping and cooperative binding through hydrogen/deuterium-exchange and molecular dynamics evidence for RRM stabilisation coupled to conserved-region destabilisation, then to sequence-space mining, cellular and patient-derived neuron models, and an in vivo reversal experiment. The score sits high in the band rather than in the top band because the in vivo advance rests on one acute overexpression paradigm and the potency gain over the prior Clip34 lead is modest.

Introduction, unknowns (a)–(e); Results, Figs. 1–6

Malat1_start emerged as the most potent natural RNA chaperone, with the lowest IC50 values against WT TDP-43 (IC50~0.36 μM)

Methodological Rigour

4.1

Controls and orthogonal methods are unusually well matched to the claims: a UG-deficient (AC)17 control RNA, the RNA-binding-deficient 5FL variant, FUS specificity testing, domain deletions, and a mouse experiment with power calculation, randomisation, blinded motor-neuron counting and stated inclusion handling. The score is held below the top band by the absence of a matched non-binding control oligonucleotide in vivo, HXMS consensus maps generated by manual percentage binning without a statistical test, and semi-quantitative 40-cycle endpoint RT-PCR for cryptic splicing.

Materials and Methods, HXMS Data Visualization; Animal Data Analysis Considerations; Spinal Delivery of RNA; RT-PCR

a peptide with a difference of less than 10% receives a score of 0, a peptide with a difference of ≥ 10% ... receives a score of −1

Reporting

4.1

The argument advances in clearly signposted steps, each closing with an explicit inference, and the abstract reports model-specific findings without asserting clinical efficacy. The score reflects in-band movement for Discussion language that reaches past the evidence, most notably the assertion of direct translational implications for symptomatic patients on the basis of a 5-day acute model.

Discussion, paragraph on in vivo reversal; Abstract

carries direct translational implications for treating patients with existing symptoms

Positioning

3.8

The paper positions itself against prior RNA-mediated TDP-43 solubilisation work and the oligonucleotide therapeutic precedent, and engages a complicating result by disqualifying (UG)17 for causing loss of function. The score is mid-band because the stated limitations do not name the invasive delivery route, the single-sex cohort, or the absence of behavioural and survival endpoints, and competing TDP-43-directed strategies are not discussed.

Discussion, limitations paragraph; Introduction, refs 13, 14, 22–24

(UG)17 prevented aggregation but interfered with TDP-43 function, disqualifying this RNA from development

Reliability

Caveats4 of 4 checks

Internal CoherenceNoted

The reported results, methods and conclusions are mutually consistent and no numerical contradiction of a central finding was identified; two minor reporting inconsistencies appear in the animal methods, and some per-panel sample sizes are deferred to figure legends that were not available for assessment.

Research ConductClean

Animal ethics approval is declared with an IACUC protocol number and PHS assurance identifier, cell and iPSC line provenance is named, antibodies and plasmids carry RRIDs, and mass spectrometry and tabulated data are deposited with resolvable identifiers. No conflict-of-interest statement appears in the supplied text, but there is no positive indicator of concealment.

Flags: 2 declared / 5 total

Reference IntegrityClean

100 references in manuscript 100 of 100 checkable references found in an index

Post-Publication RecordClean

No retraction notice found in Retraction Watch.

Last checked: 08 Oct 2026

Sources: Retraction Watch ✓

Readiness

Where this paper’s evidence sits on the path from initial observation to real-world use.

Demonstrated

Evidence spans purified protein, HEK293 cells, patient-derived motor neurons and an acute mouse model using translationally relevant 2'OMe and phosphorothioate chemistry, but delivery is by laminectomy with gelfoam application and no pharmacokinetic, toxicological, behavioural or survival data are reported. This places the work at proof-of-concept rather than approaching deployment readiness.

Materials and Methods, Spinal Delivery of RNA; RNA Oligonucleotides

replaced with a pre-saturated gelfoam sponge ... at a 100 μg/mouse dosing

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Short RNA chaperones promote aggregation-resistant TDP-43 conformers to mitigate neurodegeneration.

Key Claims

Strengths · Limitations

Mechanism supported by four orthogonal methods

Functional counter-screen disqualifies a potent candidate

Randomised, blinded, powered in vivo experiment

Breadth across disease-relevant TDP-43 forms

No matched control oligonucleotide in vivo

Single acute, single-sex in vivo model

Hydrogen-exchange differences binned without statistics

Translational limits absent from limitations section

Semi-quantitative and technical-replicate cellular readouts

Nabu Commentary

Author Note / Field Feedback

Dimension breakdown

Study Quality?

Reliability?

Readiness?

Study Quality

Reliability

Readiness